Karuna Therapeutics (Nasdaq:KRTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

KRTX Stoklara Genel Bakış

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Daha fazla detay

KRTX temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 78% daha düşük bir oranda işlem görüyor

Kazançların yılda 60.1% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $654K )

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Karuna Therapeutics, Inc. Rakipler

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$11.9b

Vaxcyte

NasdaqGS:PCVX

US$10.7b

Incyte

NasdaqGS:INCY

US$13.7b

Insmed

NasdaqGS:INSM

US$13.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Karuna Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$329.83
52 Haftanın En Yüksek Seviyesi	US$329.99
52 Haftanın En Düşük Seviyesi	US$158.38
Beta	1.15
11 Aylık Değişim	3.64%
3 Aylık Değişim	50.58%
1 Yıllık Değişim	80.73%
33 Yıllık Değişim	169.65%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	1,547.50%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Feb 20

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06

Best Performing Stocks

Sep 23

Karuna Therapeutics: This Ship Has Sailed

Sep 09

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Aug 08

Karuna Therapeutics: Front-Running KarXT Phase 3

Jun 26

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10

Hissedar Getirileri

	KRTX	US Biotechs	US Pazar
7D	3.3%	-3.7%	0.3%
1Y	80.7%	15.2%	31.1%

Getiri vs. Endüstri: KRTX geçen yıl % 15.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: KRTX geçen yıl % 31.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is KRTX's price volatile compared to industry and market?
KRTX volatility
KRTX Average Weekly Movement	13.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: KRTX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: KRTX 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 8% dan 14% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	339	Bill Meury	www.karunatx.com

Karuna Therapeutics, Inc. Temel Bilgiler Özeti

Karuna Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
KRTX temel i̇stati̇sti̇kler
Piyasa değeri	US$12.58b
Kazançlar(TTM)	-US$433.68m
Gelir(TTM)	US$654.00k

Over9,999x

P/S Oranı

-29.0x

F/K Oranı

KRTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
KRTX gelir tablosu (TTM)
Gelir	US$654.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$654.00k
Diğer Giderler	US$434.33m
Kazançlar	-US$433.68m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-11.37
Brüt Marj	100.00%
Net Kâr Marjı	-66,311.93%
Borç/Özkaynak Oranı	0%

KRTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

KRTX Stoklara Genel Bakış

Ödüller

Risk Analizi

Karuna Therapeutics, Inc. Rakipler

NasdaqGS:BMRN

US$11.9b

NasdaqGS:PCVX

US$10.7b

NasdaqGS:INCY

US$13.7b

NasdaqGS:INSM

US$13.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Co-Founder & COO exercised options and sold US$444k worth of stock